Business Wire

THALES

23.1.2024 09:01:30 CET | Business Wire | Press release

Share
Thales and Quantinuum Launch Starter Kit to help Enterprises prepare for Post-Quantum Cryptography Changes Ahead

Thales, the leading global technology and security provider, today announced the launch of its PQC Starter Kit in collaboration with Quantinuum (https://www.quantinuum.com). This first-of-its-kind offering helps enterprises prepare for Post-Quantum Cryptography (PQC). The kit provides a trusted environment for businesses to test quantum-hardened PQC-ready encryption keys and understand the implications that quantum computing will have on the security of their infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123494135/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

While 73% of organizations recognize quantum computing poses a threat to traditional cryptography, 61% have yet to define a strategy for a post-quantum world1. Post Quantum Cryptography helps mitigate this threat. As a result, organizations around the world must test their ecosystem applications, data, and devices currently relying upon traditional cryptography to ensure minimal disruption when quantum-safe protocols become mandatory.

Todd Moore, Global Head of Data Security Products at Thales commented: “Thales is excited to offer a new solution to its customers to help them prepare for the implementation of Post-Quantum Cryptography. We understand the enormous challenges and complexities behind this upcoming disruption in cryptography and want to support customers as they transition to these new algorithms.. For organizations unsure of navigating this transition, we highly recommend testing current applications, data, and devices that use cryptographic protection as soon as possible to ensure a smooth shift to PQC. Although quantum computing may seem like a future-looking risk, with hackers using Harvest Now, Decrypt Later tactics, post-quantum resilience should be on every organization’s radar today.”

"Hardening encryption keys is critical for the post-quantum era, and Quantum Origin is a unique technology that provides verifiable quantum randomness to maximize encryption key strength. The combination of Quantum Origin and the Thales HSM is a strong solution for IT teams to help them with their PQC transition. We look forward to working with Thales to help smooth the shift to PQC,” added Duncan Jones, Head of Cybersecurity at Quantinuum.

The PQC Starter Kit will allow organizations to test within a trusted lab environment. Using the current NIST proposed algorithms that are built into the system, customers can test various security use cases including PKI, code-signing, TLS, and IoT, and observe the impact of implementing PQC technology in these simulated test-lab scenarios, all without impacting operational processes in real-world production environments. Organizations will also be able to identify potential weaknesses in their encryption deployment and apply changes to their IT infrastructure to protect themselves.

The first available PQC Starter Kit option incorporates Luna HSMs and Quantinuum’s quantum random number generation (QRNG) technology through which customers can ensure their keys are securely generated and stored while testing the PQC algorithms. The kit offers a choice of Luna HSMs (i.e. appliance or PCIe card) and Quantinuum’s Quantum Origin - the world’s only source of verified quantum entropy. A PQC Starter Kit for network encryption using Thales High Speed Encryptors (HSE) will be available next.

Learn more about the PQC Starter Kit in the customer case study here.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group

1 Cybersecurity Weaknesses in Data in Motion - White Paper (thalesgroup.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123494135/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release

The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release

Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye